Blincyto (blinatumomab)

pCPA File Number: 21365
Negotiation Status:
Active Negotiation
Indication(s):
Minimal Residual Disease (MRD)-Positive B-Cell Precursor Acute Lymphoblastic Leukemia (BCP ALL)
Sponsor/Manufacturer:
Amgen Canada Inc.
CADTH Project Number:
pCODR 10204
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable